Race Oncology (ASX: RAC) is a precision oncology company with a Phase II/III cancer drug called Bisantrene.

Pharmaceutical

Race Oncology

Race Oncology's headquarters in Sydney, Australia

This department conducts research and development activities focused on scientific and medical advancements.

This department oversees the planning, execution, and management of clinical trials to ensure compliance and successful research outcomes.

This department is responsible for the strategic direction and overall management of the organization.

This department oversees medical research and operational strategy to enhance healthcare initiatives.

Race Oncology's Leadership Team includes Daniel Tillett and 1 others.